Literature DB >> 10497142

Biotransformation of doxepin by Cunninghamella elegans.

J D Moody1, J P Freeman, C E Cerniglia.   

Abstract

A filamentous fungus, Cunninghamella elegans ATCC 9245, was used as a microbial model of mammalian metabolism to biotransform doxepin, a tricyclic antidepressant drug. Doxepin is produced as an 85:15% mixture of the trans- (E) and cis- (Z) forms. After 96 h of incubation in Sabouraud dextrose broth, 28% of the drug was metabolized to 16 metabolites. No change in the trans- (E) and cis- (Z) ratio of doxepin was observed. Metabolites were isolated by reversed phase HPLC and identified by (1)H NMR and mass spectroscopic analysis. The major metabolites were (E)-2-hydroxydoxepin, (E)-3-hydroxydoxepin, (Z)-8-hydroxydoxepin, (E)-2-hydroxy-N-desmethyldoxepin, (E)-3-hydroxy-N-desmethyldoxepin, (E)-4-hydroxy-N-desmethyldoxepin, (Z)- and (E)-8-hydroxy-N-desmethyldoxepin, (E)-N-acetyl-N-desmethyldoxepin, (E)-N-desmethyl-N-formyldoxepin, (E)-N-acetyldidesmethyldoxepin, (E)-and (Z)-doxepin-N-oxide, and (E)- and (Z)-N-desmethyldoxepin. Six of the metabolites produced by C. elegans were essentially similar to those obtained in human metabolism studies, although nine novel metabolites were identified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497142

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Transformation of amoxapine by Cunninghamella elegans.

Authors:  J D Moody; D Zhang; T M Heinze; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  2000-08       Impact factor: 4.792

2.  Transformation of verapamil by Cunninghamella blakesleeana.

Authors:  Lu Sun; Hai-Hua Huang; Lei Liu; Da-Fang Zhong
Journal:  Appl Environ Microbiol       Date:  2004-05       Impact factor: 4.792

3.  Metabolism of insecticide diazinon by Cunninghamella elegans ATCC36112.

Authors:  Mei-Ai Zhao; Hao Gu; Chuan-Jie Zhang; In-Hong Jeong; Jeong-Han Kim; Yong-Zhe Zhu
Journal:  RSC Adv       Date:  2020-05-26       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.